The user is experiencing a greasy and dandruff-prone scalp from using RU58841 with glycerin and is seeking alternative carriers for seborrheic dermatitis. They are also using dutasteride 0.5mg.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
The conversation humorously discusses hair loss treatments, mentioning scalp massage, minoxidil, and the ineffectiveness of devices like the "Gr0wBand." It highlights the role of androgens in hair loss and suggests that increased blood flow from massage may not significantly impact hair growth.
The conversation is about creating a DIY topical finasteride solution using ethyl alcohol and propylene glycol. A user suggests using a compounding pharmacy instead.
A 24-year-old shared their 7-month progress using a topical solution of finasteride 0.1%, minoxidil 5%, and hydrocortisone butyrate 0.08%, along with ketoconazole shampoo, to treat hair loss, reporting no side effects and noticeable hair improvement. They also take vitamin D and biotin supplements, use a dermastamp, and manage Hashimoto's without thyroid medication.
A user switched from a 1.5 mm derma roller to an adjustable dermastamp for microneedling to treat hair loss and found it less painful and more effective. Some users prefer different depths and tools like the Dr.Pen for microneedling, while others debate the necessity of depth and tool type.
The conversation discusses the use of pyrilutamide as an adjunct treatment for hair loss, particularly for those already using finasteride and minoxidil. Users share mixed experiences, with some reporting side effects like numbness and gynecomastia, while others note its potential benefits in reducing shedding and scalp itchiness.
The conversation discusses the use of ethanol and propylene glycol (PG) in topical solutions for hair loss treatments, specifically Minoxidil. The user dislikes the texture of PG and questions the ideal ratio and necessity of PG in these solutions.
A user is experimenting with a DIY topical solution combining finasteride and minoxidil for hair loss, applying 0.5 mg of finasteride daily. Concerns include absorption issues, potential side effects, and product loss due to hair density, with some users suggesting oral intake for better results.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
A user is seeking advice on increasing graft survivability after a hair transplant, mentioning PRP, Mesotherapy, Stem Cell injections, and considering L-Arginine before starting Minoxidil. They are looking for ways to support blood flow before applying Minoxidil.
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
Microneedling is effective for hair growth, especially when combined with finasteride and minoxidil, but concerns exist about potential long-term skin damage. Users report increased collagen and elastin deposition, but the long-term effects on the scalp remain uncertain.
Breezula/Winlevi's potential use for hair loss is discussed, with concerns about its effectiveness compared to Breezula's higher concentration. Users express interest in a topical treatment with minimal side effects, noting that Breezula's efficacy may decline after six months.
Minoxidil foam absorption concerns, with suggestions to use gloves or apply directly to the scalp to ensure proper absorption. Some users recommend using a scalp massager or switching to liquid minoxidil for better application.
The user experienced hair regrowth using Koshine KX-826 after two months, noticing new baby hairs and reduced shedding, while continuing to use Hims spray. They reported no side effects from Koshine and plan to keep monitoring progress.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.
The user has trouble applying minoxidil foam to their long, curly hair and experiences product buildup, leading to frequent hair washing. They are considering switching to liquid minoxidil but are concerned about scalp sensitivity and do not want to use oral treatments. Another user suggests that topical minoxidil doesn't need to be applied to the entire scalp to be effective.
A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
PP405 shows promise in reactivating dormant hair follicles, with 31% of users experiencing a 20% increase in hair density in a short period. It may work faster than minoxidil and without side effects, but its long-term effectiveness is still uncertain.
A user shared their positive experience with a 4200-graft hair transplant performed by Dr. Heena Kudyar, noting significant improvement in hairline and density by month 9. The user did not mention using medications like Minoxidil, Finasteride, or RU58841.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.
A user in Poland created a homemade "oral topical minoxidil" using 2% topical minoxidil, propylene glycol, and vodka due to difficulty obtaining oral minoxidil. They shared a recipe and sought feedback, emphasizing caution and safety in dosing.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.